Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-195

James, From memory the presentation covering the next Azer-cel trial was due to start in April 24. So by starting this week and reduced to 10 pax we should finish much earlier than previously predicted. The 13 hospitals and the enrolling Oncologist are all still in place. They should be already scouting for patients. They’ve known this is coming and also known the results so far have been outstanding.

So Azer-Cel could move very fast through the registrational trials to market.

So IMU will probably be fielding calls to BP sounding out their best options for selling and distributing AZER-Cel. I just can’t see PH recruiting a sales team here.

SOA deal within months is on the cards. ACAD who have the license for NEU’s drug started recruiting and building out their infrastructure at least 12 months in advance of FDA approval.

Monil Shah will be out now chasing his first commercial deal. This will come with a big upfront cheque. With a market size of US$2.5bn it will be a real prize for a BP. NEU’s drug only had and estimated market size of $500M. So it’s easy to understand just how much competition there will be amongst the Oncology focussed companies to get their hands on Azer-Cel.

Yesterday’s run up to .15 was well justified by this PS announcement. However all the traders dumped it back to .105 . But for those long term fundies who follow this stuff will know that a lot of value was added to IMU with this announcement.